Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 25.00 as of 2026-10-06T20:58:08.041Z.
Consensus retrieved: 2026-10-06T15:06:33.820Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T20:58:08.041Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7ec899be3b20195a496e3f3723b900c99a18170c8b18d4f0df40018ca706fe4d
Forward PE Ratio (25.00) = Dated Quote Price ($9.50) / Consensus Forward EPS ($0.38)
FORWARD PE RATIO
25.00
SECTOR MEDIAN · HEALTHCARE
19.79
median of 190 covered companies
CURRENT VS SECTOR MEDIAN
+26.36%
vs the sector median at left
Puma Biotechnology, Inc.
Market Cap
$483.54M
Forward PE Ratio
25.00
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Puma Biotechnology, Inc. (PBYI) | $483.54M | 25.00 |
| Evolus, Inc. (EOLS)vs › | $486.01M | N/A |
| Contineum Therapeutics, Inc. (CTNM)vs › | $475.91M | N/A |
| Bright Minds Biosciences Inc. (DRUG)vs › | $472.23M | N/A |
| Arvinas, Inc. (ARVN)vs › | $471.65M | N/A |
| Cerus Corporation (CERS)vs › | $471.57M | N/A |
| Alpha Teknova, Inc. (TKNO)vs › | $469.12M | N/A |
| Oculis Holding AG (OCS)vs › | $498.52M | N/A |
| Kamada Ltd. (KMDA)vs › | $467.90M | 16.98 |
| Tactile Systems Technology, Inc. (TCMD)vs › | $500.52M | 19.87 |
Trailing P/E
18.4
reported TTM EPS
Forward P/E
25.0
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $0.38 implies -26.9% EPS decline vs the reported trailing $0.52.
At the dated quote price of $9.50, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.38 | $0.38 – $0.38 | 1 | 25.0x |
| 2027-12-31 | $0.20 | $0.20 – $0.20 | 1 | 47.5x |
| 2028-12-31 | $0.15 | $0.15 – $0.15 | 1 | 63.3x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
